Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00036270
Status:
COMPLETED
Last Update Posted:
2015-10-28
First Post:
2002-05-08
Brief Title:
Randomized Phase III Study Of Exemestane Aromasin For 5 Years Versus Tamoxifen for 25 to 3 Years Followed By Exemestane
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Randomized Phase III Study Of Exemestane Aromasin For 5 Years Versus Tamoxifen For 25- 3 Years Followed By Exemestane Aromasin For A Total Of 5 Years As Adjuvant Therapy For Postmenopausal Receptor Positive Node Negative or Node Positive Breast Cancer Patients
Status:
COMPLETED
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TEAM
Brief Summary:
To compare the effects of exemestane for 5 years versus tamoxifen and exemestane given sequentially over 5 years in the adjuvant treatment of postmenopausal women with early breast cancer
This Pfizer sponsored trial is part of an international collaboration of investigators conducting 7 similar yet independent studies in 9 countries This study is designed to be part of the larger TEAM trial where the data from these 7 studies will be combined A pre-specified analysis of the pooled data will be conducted
This Pfizer sponsored trial is part of an international collaboration of investigators conducting 7 similar yet independent studies in 9 countries This study is designed to be part of the larger TEAM trial where the data from these 7 studies will be combined A pre-specified analysis of the pooled data will be conducted
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| A5991026 | None | None | None |